MedTrace Logo

Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE

NCT04161287 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2024-02-02

No results posted yet for this study

Summary

The study aims to compare efficacy and adverse reactions of hepatocellular carcinoma participants (≤5cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.

Conditions

  • Small Hepatocellular Carcinoma
  • Stereotactic Body Radiation Therapy
  • Transcatheter Arterial Chemoembolization

Interventions

PROCEDURE

transcatheter arterial chemoembolization

The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Xuezhang Duan, PH.D · Beijing 302 Hospital

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-11
Primary Completion
2023-12-11
Completion
2025-01-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161287 on ClinicalTrials.gov